Clinical Trial

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-09.
Status change: Not Yet Recruiting → Recruiting 2026-01-08
Trial Details
NCT Number NCT07073638
Lead Sponsor Thirty Respiratory Limited
Conditions Pulmonary Tuberculoses
Enrollment 24 participants
Start Date 2025-10-13
Primary Completion 2026-09-15 (estimated)
Study Completion 2026-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-12